Remdesivir: A Review in COVID-19.
- Published in:
- Drugs, 2023, v. 83, n. 13, p. 1215, doi. 10.1007/s40265-023-01926-0
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2023 AND VI 83 AND IP 13
Results: 8
1
2
Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus.
- Published in:
- Drugs, 2023, v. 83, n. 13, p. 1161, doi. 10.1007/s40265-023-01925-1
- By:
- Publication type:
- Article
3
Correction to: Concizumab: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
4
Sovateltide: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 13, p. 1239, doi. 10.1007/s40265-023-01922-4
- By:
- Publication type:
- Article
5
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study.
- Published in:
- Drugs, 2023, v. 83, n. 13, p. 1207, doi. 10.1007/s40265-023-01918-0
- By:
- Publication type:
- Article
6
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
- Published in:
- Drugs, 2023, v. 83, n. 13, p. 1179, doi. 10.1007/s40265-023-01916-2
- By:
- Publication type:
- Article
7
Recent Advances in Antiarrhythmic Drug Therapy.
- Published in:
- Drugs, 2023, v. 83, n. 13, p. 1147, doi. 10.1007/s40265-023-01923-3
- By:
- Publication type:
- Article
8
Sulbactam/Durlobactam: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 13, p. 1245, doi. 10.1007/s40265-023-01920-6
- By:
- Publication type:
- Article